In a clinical setting, hypoglycemic drugs such as sodium-glucose cotransporter 2 inhibitors (SGLT2i) (Empagliflozin, Canaglifozin, Ipragliflozin and Dapagliflozin) [40], and glucagone-like peptide-1 (GLP-1) receptor analogs (Liraglutide, Semaglutide, Exenatide, and Albiglutide) [41], or other drugs such as IL-1β antibodies antagonist (Canakinumab or Gevokizumab) [42], and recombinant IL-1β receptor antagonist (Anakinra) [43] decrease cardiovascular events and mortality in patients with type-2 diabetes [1,3,41,43]. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.